Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 480-370-1 | CAS number: 21743-27-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Toxicity to reproduction
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Remarks:
- other: OECD 408 (Repeated Dose 90-Day Oral Toxicity in Rodents)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2011-03-24 to 2012-10-02
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: OECD test under GLP
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
- Report date:
- 2012
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: OECD 408 (Repeated Dose 90-Day Oral Toxicity in Rodents)
- Deviations:
- yes
- Remarks:
- Additional fertility parameters were evaluated as was discussed and accepted during the ECHA test proposal procedure instead of conducting a separate reproductive screening study.
- Principles of method if other than guideline:
- not applicable
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- -
- EC Number:
- 480-370-1
- EC Name:
- -
- Cas Number:
- 21743-27-1
- Molecular formula:
- Hill formula: C11H25NO4Si CAS formula: C11H25NO4Si
- IUPAC Name:
- 4-[(triethoxysilyl)methyl]morpholine
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, 97633 Sulzfeld, Germany
- Age at study initiation: 7-8 weeks
- Weight at study initiation: males: 188 - 251 g , females: 152 - 194 g
- Housing: full barrier in an air conditioned room
- Diet (e.g. ad libitum): at libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 3 °C
- Humidity (%): 55 +/- 10%
- Air changes (per hr): 10/h
- Photoperiod (hrs dark / hrs light): 12 h dark, 12 h light
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- VEHICLE
- Justification for use and choice of vehicle (if other than water): The vehicle was selected as suggested by the sponsor based on the test item’s characteristics and testing guideline. - Details on mating procedure:
- Not applicable for the test guideline followed.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Does verification was performed by quantification of the test item using AAS. The fortification level covered approximately 112, 306 and 1000 mg test item/ 5 ml corn oil.
- Duration of treatment / exposure:
- Test duration: 90 days.
- Frequency of treatment:
- Dosing regime: 7 days/week
- Details on study schedule:
- Not applicable for the test guideline followed.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 100, 300, 1000 mg/kg bw/day (m/f)
Basis:
actual ingested
- No. of animals per sex per dose:
- Male: 15 animals at 0 mg/kg bw/day
Male: 10 animals at 100 mg/kg bw/day
Male: 10 animals at 300 mg/kg bw/day
Male: 15 animals at 1000 mg/kg bw/day
Female: 15 animals at 0 mg/kg bw/day
Female: 10 animals at 100 mg/kg bw/day
Female: 10 animals at 300 mg/kg bw/day
Female: 15 animals at 1000 mg/kg bw/day - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: results of a 28-day repeated dose oral toxicity study (BSL study no. 071114) and an oral prenatal developmental toxicity study which was performed at Harlan Laboratories Ltd
- Post-exposure recovery period in satellite groups: 5 animals per gender of the control and of the HD group (1000 mg/kg bw/day) served as recovery group - Positive control:
- No.
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS:
Detailed cage side observations considering spontaneous activity, lethargy, recumbent position, convulsions, tremors, apnoea, asphyxia, vocalisation, diarrhoea, changes in skin and fur, eyes and mucous membranes (salivation, discharge), piloerection and pupil size were made outside the home cage in a standard arena once before the first administration and at least once a week thereafter
DETAILED CLINICAL OBSERVATIONS: Yes
General clinical observations were made at least once a day, preferably at the same time each day. The health condition of the animals was recorded. Twice daily all animals were observed for morbidity and mortality except for weekends and public holidays when observations were made once daily.
Changes in gait, posture, response to handling as well as the presence of clonic or tonic movements, stereotypies or bizarre behaviour were recorded.
BODY WEIGHT: The body weight was recorded once before the assignment to the experimental groups, on the first day of administration and weekly during the treatment and recovery period.
FOOD CONSUMPTION:
Food consumption was measured weekly during the treatment and recovery period.
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: Ophthalmological examination, using an ophthalmoscope, were made on all animals before the first administration and in the last week of the treatment period as well as at the end of the recovery period in the recovery animals.
HAEMATOLOGY: Yes
- Time schedule for collection of blood: day of necropsy
- Anaesthetic used for blood collection: ketamine, Bremer Pharma GmbH, lot no: 29116, expiry date: July 2012 and xylazin, Riemser Arzneimittel AG, lot no. 000660/1, expiry date: December 2011
- Animals fasted: Yes
- How many animals: all
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: day of necropsy
- Animals fasted: Yes
- How many animals: all
URINALYSIS: Yes
- Time schedule for collection of urine: day of necropsy
- Metabolism cages used for collection of urine: No
- Animals fasted: Yes
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations:Once before the first exposure and once during the last week of the treatment period multiple detailed behavioural observations were made outside the home cage using a functional observational battery of tests [8]. These tests were additionally performed in the 4th week after the end of the treatment period on the animals that were sacrificed at the end of the recovery period.
- Dose groups that were examined: 0, 100, 300, 1000 mg/kg bw/day - Oestrous cyclicity (parental animals):
- Daily over a period of 8 days, the estrous cycle of female animals, excluding the animals to be evaluated at the end of the recovery period, were examined at the beginning of the second month of treatment, (study week 5), at the beginning of the third month of treatment (study week 9) and at the end of the treatment period (study week 13). In the recovery animals the estrous cycle was examined during the last week of the recovery period (study week 17).
- Sperm parameters (parental animals):
- At necropsy at the end of the treatment period and at the end of the recovery period (see 11.18), one epididymis of each male animal was separated and immediately used for evaluation of epididymal sperm motility. At necropsy also one testis was separated and deep frozen in liquid nitrogen and stored at <-70°C until evaluation of testicular sperm count. All sperm parameters were analyzed using Hamilton Thorn Sperm Analyser (TOX IVOS Version 12.3).
Gross necropsy:
After weighing, one testis and one epididymis was separated and used for the evaluation of sperm parameters (11.13).
Histopathology:
For testis, a detailed qualitative examination was made, taking into account the tubular stages of the spermatogenic cycle at evaluation of additional hematoxylin-PAS (Periodic Acid Schiff) stained slides. - Litter observations:
- Not applicable for the test guideline followed.
- Postmortem examinations (parental animals):
- GROSS PATHOLOGY: Yes
All animals in the study were subjected to a full, detailed gross necropsy which included careful examination of the external surface of the body, all orifices and the cranial, thoracic and abdominal cavaties and their contents.
HISTOPATHOLOGY: Yes
Full histopathology was carried out on the preserved organs and tissues of all animals in the Control (0 mg/kg bw/day) and High Dose (1000 mg/kg bw/day) groups. Additionally, kidneys, lungs, bone marrow (sterum) and adrenal glands were examinated histopathologically in male animals of the 100 mg/kg bw/day and 300 mg/kg bw/day groups. A full histopathological evaluation was also performed on animal no. 23 of the 300 mg/kg bw/day group that had died during the treatment period - Postmortem examinations (offspring):
- Not applicable for the test guideline followed.
- Statistics:
- Not applicable.
- Reproductive indices:
- Not applicable for the test guideline followed.
- Offspring viability indices:
- Not examined.
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- s. below under
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Body weight : s. below under ; food consumption: no effects
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Body weight : s. below under ; food consumption: no effects
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- s. below under
- Other effects:
- no effects observed
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- not examined
- Description (incidence and severity):
- Not applicable for the test guideline followed.
Details on results (P0)
One male animal of the MD group died on study day 85 of the treatment period, due to severe renal inflammation and scarring and a subsequent systemic inflammatory state with secondary myocarditis. Prior to death slightly reduced spontaneous activity, moderate to severe piloerection and slight body weight loss were observed in this animal.
Besides, no test item related clinical signs were noted during this study
BODY WEIGHT AND WEIGHT GAIN
Neither in male nor in female animals where there any statistically significant or biologically relevant differences between the dose groups and the control group in body weight development or food consumption. Mean daily body weight gain of male animals of the HD group was slightly and statistically significantly attenuated when compared to controls at the end of the treatment period.
ORGAN WEIGHTS
Kidneys of male animals of the HD group were moderately higher in weight than control animals. This was most prominent in animals showing histopathological alterations (see below). The effect on kidney weight of male animals was completely reversible at the end of the recovery period. Kidney weight in female animals - although slightly lower than in the respective controls, is not assumed to be affected by (N-Morpholinomethyl)triethoxysilan.
Adrenal glands in female animals of all dose groups were slightly lower in weight than in control animals. At the end of the recovery period no significant difference in adrenal gland weight of the female animals was found between HD groups and controls. As no associated histopathological findings were noted, a relation to the test item is unclear.
Slightly – but statistically significantly lower absolute spleen weight was seen in female – but not male animals, mainly in MD and HD group. At the end of the recovery period no significant difference in spleen weight of the female animals was found between HD groups and controls.
GROSS PATHOLOGY
At the end of the treatment period macroscopic alteration in the kidney were observed in 3/10 male animals of the HD group: A slightly abnormally shaped or an enlarged and yellow mottled kidney or multiple yellowish pin-point foci. Besides, no gross test item related alterations were observed at the end of the treatment or recovery period of this study.
HISTOPATHOLOGY: NON-NEOPLASTIC
Treatment at 300 mg/kg/day led to the spontaneous death of one male rat towards the end of the treatment period, caused by severe renal inflammation and scarring and a subsequent systemic inflammatory state with secondary myocarditis.
In five males treated at 1000 mg/kg/day, a multifocal interstitial nephritis/scarring was observed, its severity ranging from mild to severe. It was associated with multifocal dilated cortical tubules, and with an increase in basophilic tubules and mononuclear cell infiltrates, when compared to control males. Minor lesions of the pelvic urothelium were also noted, comprising suburothelial mononuclear cell infiltrates and a multifocal to diffuse urothelial hyperplasia. At 300 mg/kg/day, a mild interstitial nephritis/scarring, associated with mild numbers of basophilic tubules and mild mononuclear cell infiltrates, was observed in one single male and was also considered test item-related. The mechanism of the renal changes could not be elucidated in this study.
In the bone marrow, a minimally increased myeloid:erythroid ratio was seen in two males treated at 1000 mg/kg/day and was considered to be a borderline reaction to the renal inflammation observed in the same animals. It was therefore not considered to be directly test item-related.
In the lung of male rats treated at 1000 mg/kg/day, there was a tendency towards higher severity grades of multifocal alveolar macrophages, perivascular/peribronchial mixed cell infiltrates and foci of pneumonitis, when compared to the background level seen in controls. A multifocal minimal epithelialization was seen in three males. In view of their low incidence and degree, the significance of the pulmonary findings is not clear, but a direct toxic effect of the test item on the lung cannot be fully excluded.
After the 28-day recovery period, renal lesions were found to be partially and lung lesions were found to be completely reversible. Bone marrow changes had not yet resolved.
Effect levels (P0)
- Key result
- Dose descriptor:
- NOEL
- Remarks:
- for reproductive effects
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: A reproduction toxicological effect of (N-Morpholinomethyl)triethoxysilan was not found in this study.
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- not examined
- Description (incidence and severity):
- Not applicable for the test guideline followed.
- Mortality / viability:
- not examined
- Description (incidence and severity):
- Not applicable for the test guideline followed.
- Body weight and weight changes:
- not examined
- Description (incidence and severity):
- Not applicable for the test guideline followed.
- Sexual maturation:
- not examined
- Description (incidence and severity):
- Not applicable for the test guideline followed.
- Organ weight findings including organ / body weight ratios:
- not examined
- Description (incidence and severity):
- Not applicable for the test guideline followed.
- Gross pathological findings:
- not examined
- Description (incidence and severity):
- Not applicable for the test guideline followed.
- Histopathological findings:
- not examined
- Description (incidence and severity):
- Not applicable for the test guideline followed.
Details on results (F1)
Effect levels (F1)
- Remarks on result:
- other: no offspring generation created in this study
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
Any other information on results incl. tables
Fertility Parameters
(N-Morpholinomethyl)triethoxysilan had no effect on epididymal sperm motility or testicular sperm count analyzed at the end of the treatment or recovery period of this study. Neither in the percentage of motile, static or rapidly moving epididymal sperms nor in testicular number of sperms/g testis was there any statistically significance between control and any of the dose groups.
(N-Morpholinomethyl)triethoxysilan had also no effect on the oestrus cycle analyzed in study weeks 5 or 9 or at the end of the treatment or recovery period. Considering individual values, there was no considerable difference in cycle length or sequence of cycle stages between dose groups and the control group.
Applicant's summary and conclusion
- Conclusions:
- In a reliable 90-day repeated dose toxicity study with (N-Morpholinomethyl)triethoxysilan, conducted according to OECD test guideline 408 and in compliance with GLP, there were no effects on any of the reproductive organs examined in male or females (testes, epididymis, ovaries, uterus), at any dose level up to the highest test concentration of 1000 mg/kg bw.day. Furthermore, there were no effects on any of the additional fertility parameters investigated as well.
- Executive summary:
In a 90-day repeated oral dose toxicity study with the test item (N-Morpholinomethyl)triethoxysilan groups of 10 male and female Wistar rats were exposed to 0, 100, 300 and 1000 mg/kg bw/day by gavage with corn oil as the vehicle.
Histopathological findings directly attributed to the test item were seen in the kidney of males treated at 1000 and 300 mg/kg/day.
At 300 mg/kg/day, one surviving male rat showed also kidney lesions considered test item-related, and another male died spontaneously of severe renal pathology with secondary myocarditis. Renal lesions were partially reversible after 28 days. A minimally increased myeloid:erythroid ratio of the bone marrow was considered indicative of increased myelopoiesis in individuals presenting prominent renal lesions, and was therefore considered indirectly test item-related. It was not reversible after 28 days. The significance of some minor pulmonary lesions seen in males at 1000 mg/kg/day could not be elucidated, a test item relationship cannot be excluded. Pulmonary lesions had resolved after 28 days without treatment.
Further associated findings in the HD group were: macroscopic findings in the kidney, slightly higher kidney weight and increase in blood urea and creatinine in male animals. Finally, overall body weight gain was slightly attenuated in male animals.
On the basis of these findings, the kidney can be considered the major target organ of (N-Morpholinomethyl)triethoxysilan.
A reproduction toxicological effect of (N-Morpholinomethyl)triethoxysilan was not found in this study.
A slightly lower weight in adrenal glands of female animals of all dose groups and a slightly higher spleen weight in female animals of the MD and HD group cannot not be elucidated but was absent at the end of the recovery period. A relation to the test item is unclear.
The dose level of 100 mg/kg/day marks the NOAEL for systemic toxicity in this study.
As no reproduction toxicological effect was found in this study, the dose level of 1000 mg/kg/day marks the NOEL
for reproductive effects.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)